Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistant Acinetobacter baumannii infections.

Vineet DubeyKuldip DevnathVivek K GuptaGazal KalyanMangal SinghAshish KothariBalram Ji OmarRanjana Pathania

Published in: The Journal of antimicrobial chemotherapy (2022)

These results strongly suggest that the combination of disulfiram and meropenem represents an effective treatment option for NDM- and IMP-associated CRAb infections.

Keyphrases

acinetobacter baumannii
multidrug resistant
klebsiella pneumoniae
gram negative
drug resistant
pseudomonas aeruginosa
escherichia coli
combination therapy
smoking cessation
replacement therapy